Antiemetics

Publication Date: July 13, 2020

Key Points

Key Points

  • The development of increasingly effective antiemetic regimens over the last quarter century has greatly reduced the incidence of nausea and vomiting due to chemotherapy.
  • The recommended approach to preventing nausea and vomiting varies by the emetic risk of the treatment regimen.
  • Adherence to antiemetic guidelines has been linked with improved control of nausea and vomiting.
  • This update of the 2017 guideline adds guidance on the use of dexamethasone as a prophylactic antiemetic in patients receiving checkpoint inhibitors (CPIs).

Treatment

...reatment...

...lt Patient...

...adult patients, the addition of a checkpoint...

...gh-Emetic-Risk Antineoplastic Agents

...reated with cisplatin and other high-emetic-risk...

...patients treated with an anthracycline combined...

...tic-Risk Antineoplastic Agents...

...tients treated with carboplatin area under...

...reated with moderate-emetic-risk antineoplastic ag...

...nts treated with cyclophosphamide, doxorubici...

...tic-Risk Antineoplastic Agents...

...t patients treated with low-emetic-risk antineo...

...mal Emetic Risk Antineoplastic Agents...

...treated with minimal emetic risk antineoplastic ag...

...oplastic Combinations...

...tients treated with antineoplastic combinat...

...djunctive Drug...

...zepam is a useful adjunct to antiemetic drugs,...

Cannabinoids

...s insufficient for a recommendation reg...

...ry and Alternative Therapies...

...ce remains insufficient for a reco...

...herapy With Stem-Cell or Bone Marrow Tr...

...lt patients treated with high-dose chemothe...

...g combination of an NK1 receptor an...

...y Antineoplastic Therapy...

Adult patients treated with multiday anti...

...ients treated with 4- or 5-day cisp...

...ough Nausea and Vomiting...

...with breakthrough nausea or vomiting, cl...

...ents who experience nausea or vomit...

...abinol and nabilone ( IC , I , M )6539...

...( IC , L , M )6539...

...ipatory Nausea and Vomiting

...should receive the most active ant...

...igh Emetic Risk Radiation Thera...

...nts treated with high-emetic-risk radiation ther...

Moderate Emetic Risk Radiation T...

...treated with moderate-emetic-risk radiation th...

...Emetic Risk Radiation Thera...

...ult patients treated with radiation ther...

...al Emetic Risk Radiation Therapy...

...patients treated with minimal eme...

...urrent Radiation and Antineoplastic Agent The...

...ult patients treated with concurrent...


...tric Patient...

...metic Risk Antineoplastic...

...Pediatric patients treated with high-emetic-ri...

...ated) Pediatric patients treated with high-emetic-...

...ted) Pediatric patients treated with high-em...

...metic Risk Antineoplastic Agents...

...patients treated with moderate-emetic-risk antineo...

...Pediatric patients treated with moderate-eme...

...Risk Antineoplastic Agents...

...atric patients treated with low-emetic-r...

...Emetic Risk Antineoplastic Agents...

...diatric patients treated with minimal emeti...


...etic Risk of Single Intravenous Antineoplastic...


...c Risk of Single Oral Antineoplasti...


...ble 3. Antiemetic Dosing for Adults by Ch...


...le 4. Emetic Risk in Adults by Site of...


...iemetic Administration in Adults by R...